Text Size

Research of the EML4-ALK Gene Expression in the Pleural Effusion or Tumor Tissue From Lung Cancer Patients

This study is enrolling participants by invitation only.
Sponsor:
Information provided by:
Taipei Medical University WanFang Hospital
ClinicalTrials.gov Identifier:
NCT01257308
First received: December 8, 2010
Last updated: NA
Last verified: December 2010
History: No changes posted
  Purpose

We wants to analyse the EML4-ALK mutation rate in the patients who have non-small cell lung cancer.


Condition
Lung Cancer Patients

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Research of the EML4-ALK Gene Expression in the Pleural Effusion or Tumor Tissue From Lung Cancer Patients

Resource links provided by NLM:

MedlinePlus related topics: Cancer Lung Cancer
U.S. FDA Resources

Further study details as provided by Taipei Medical University WanFang Hospital:

Estimated Enrollment: 100
Study Start Date: August 2010
Estimated Study Completion Date: August 2013
  Eligibility

Ages Eligible for Study:   20 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Lung Cancer Patients

Criteria

Inclusion Criteria:

  • 20 or more than 20 years of age
  • The pathological diagnosis confirmed lung cancer
  • Patients have achieved pleural effusion, or surgical biopsy to obtain tumor tissue specimens
  • The patient had signed inform consent

Exclusion Criteria:

  • pleural effusion or tumor tissue can not be obtained
  • the patient is not suitable to join the research according to the judgement by the investigator
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01257308

Locations
Taiwan
Taipei Medical University - WanFang Hospital
Taipei, Taiwan
Sponsors and Collaborators
Taipei Medical University WanFang Hospital
Investigators
Principal Investigator: Hsin-Gjin Eugene Liu Taipei Medical University WanFang Hospital
  More Information

No publications provided

Responsible Party: Hsingjin Eugene Liu, MD PhD, Taipei Medical University WanFang Hospital
ClinicalTrials.gov Identifier: NCT01257308     History of Changes
Other Study ID Numbers: 99047
Study First Received: December 8, 2010
Last Updated: December 8, 2010
Health Authority: Taiwan: Department of Health

Keywords provided by Taipei Medical University WanFang Hospital:
lung cancer

Additional relevant MeSH terms:
Lung Neoplasms
Pleural Effusion
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
 Neoplasms
Lung Diseases
Respiratory Tract Diseases
Pleural Diseases

ClinicalTrials.gov processed this record on May 19, 2013